Trade Desk Inc vs GeneDx Holdings Corp — how do they compare? Trade Desk Inc trades at $13.46 (market cap $6.37B), while GeneDx Holdings Corp trades at $82.5 (market cap $2.44B). The key difference: Trade Desk Inc is far larger — about 2.6× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| TTD | WGS | |
|---|---|---|
Market Cap | $6.37B | $2.44B |
Sector | Technology | Technology |
52-Week High | $55.36 | $167.51 |
52-Week Low | $13.39 | $34.51 |
Enterprise Value | $5.32B | $2.48B |
Signals from Pluang's Aura AI — not financial advice
The Trade Desk (TTD) stock trades at $13.39, down 2.97% today and near 52-week lows after a sharp 90% decline from its 2024 peak. Recent Q2 2026 earnings missed expectations with 3% revenue growth and weak Q3 guidance, triggering analyst downgrades. Technical indicators are bearish, with support at $12. The company maintains strong profitability margins but faces growth deceleration and competitive pressures in digital advertising.
Outlook remains cautious due to execution gaps and macroeconomic headwinds. While valuations appear reasonable with a P/E of 16.14, near-term risks from revenue declines and advertiser pullbacks outweigh potential upside. Investors should monitor Q3 earnings for signs of stabilization before considering entry.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →